Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Jens Sydor
Advertisement
Jens Sydor is vice-president, DMPK, GlaxoSmithKline.
Articles by Jens Sydor
Advertisement
Latest Updated Articles
Advertisement
Advertisement